ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference taking place virtually from February 10-11, 2023. New data will be presented from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314 delivered subretinally using cGMP material produced by the REGENXBIO NAVXpress™ platform process to support future commercialization.

The presentations will be as follows:

Presentation Title: Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase II Pharmacodynamic Study
Presenter: Charles C. Wykoff, M.D., PhD, Retina Consultants of Texas
Date/Time: Saturday, February 11, 2023, 8:40 a.m. ET

Presentation Title: Long-Term Follow-Up of Durable Subretinal RGX-314 Gene Therapy for Exudative AMD
Presenter: Allen C. Ho, M.D., Director of Retina Research, Wills Eye Hospital, Mid Atlantic Retina
Date/Time: Saturday, February 11, 2023, 8:50 a.m. ET

Presentation Title: Suprachoroidal Therapy for Diabetic Retinopathy
Presenter: Peter A. Campochiaro, M.D., Director, Retinal Cell and Molecular Laboratory
Professor of Ophthalmology, John Hopkins School of Medicine
Date/Time: Saturday, February 11, 2023, 10:40 a.m. ET

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5 x '25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.


Dana Cormack
Corporate Communications 

Chris Brinzey
ICR Westwicke

(PRNewsfoto/REGENXBIO Inc.)

Cision View original content to download multimedia:


Copyright 2023 PR Newswire

Historical Stock Chart
From Mar 2023 to Mar 2023 Click Here for more REGENXBIO Charts.
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more REGENXBIO Charts.